On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025) U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage...Read more
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally TMJ causes pain and stiffness in the jaw, making it difficult to chew TMJ...Read more
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global,...Read more
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion...Read more
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P<0.0001) vs. placebo with improvements seen at...Read more
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Molina Healthcare | 24.75 7.53 | $353.24 |
| McKesson | 23.40 3.37 | $716.93 |
| Elevance Health | 23.36 5.44 | $452.69 |
| UnitedHealth | 17.24 3.30 | $540.44 |
| Aclarion | 11.37 1,516.00 | $12.12 |
| Cigna | 6.53 1.97 | $338.45 |
| argenx | 6.44 1.10 | $590.06 |
| Chemed | 4.53 0.74 | $619.21 |
| Johnson & Johnson | 4.46 2.87 | $159.82 |
| Amgen | 4.15 1.36 | $309.85 |
| Centene | 3.56 5.86 | $64.29 |
| Quest Diagnostics | 2.67 1.59 | $170.63 |
| OpGen | 2.30 121.05 | $4.20 |
| HCA Healthcare | 2.11 0.61 | $349.14 |
| AstraZeneca | 1.70 2.35 | $73.92 |
| Ensign | 1.65 1.25 | $133.90 |
| Tivic Health Systems | 1.57 48.31 | $4.82 |
| Novartis | 1.49 1.35 | $112.26 |
| Company | Volume | Last Trade |
|---|---|---|
| Protagenic Therapeutics | 176,872,541 | $0.42 |
| Aptevo Therapeutics | 75,985,574 | $2.01 |
| Genprex | 61,673,818 | $0.43 |
| Sharps Technology | 54,646,882 | $0.03 |
| Pfizer | 49,050,196 | $24.30 |
| Tivic Health Systems | 34,534,578 | $4.82 |
| Walgreens Boots Alliance | 21,933,371 | $11.06 |
| Aldeyra Therapeutics | 21,823,177 | $1.46 |
| Recursion | 18,045,736 | $4.82 |
| Johnson & Johnson | 12,890,890 | $159.82 |
| Bristol-Myers Squibb | 12,832,770 | $57.75 |
| Moderna | 12,576,105 | $25.73 |
| Sangamo Therapeutics | 12,453,278 | $0.62 |
| CVS Health | 11,903,833 | $67.51 |
| Boston Scientific | 10,825,682 | $98.50 |
| Iovance Biotherapeutics | 10,718,450 | $3.25 |
| Viatris | 10,525,283 | $8.16 |
| GSK | 10,383,283 | $39.01 |
| Roivant | 10,285,148 | $10.01 |
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
